# Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

> **NCT00107718** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 64 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** SB-485232

## Key facts

- **NCT ID:** NCT00107718
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11-15
- **Primary completion:** 2006-05-19
- **Final completion:** 2006-05-19
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107718, "Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00107718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*